Aura Biosciences, Inc. Increase (Decrease) in Accrued Liabilities
Aura Biosciences, Inc. (AURA) reported Increase (Decrease) in Accrued Liabilities of $423.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-11
- Aura Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $3.17M, a 6.41% decline year-over-year.
- Aura Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$2.75M.
- Aura Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$124.00K.
- Aura Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $3.35M, a 6.46% increase year-over-year.
- Aura Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $4.13M, a 161.95% increase from fiscal 2024.
- Aura Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $1.58M, a 52.36% decline from fiscal 2023.
- Aura Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $3.31M, a 1314.53% increase from fiscal 2022.
- Aura Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $234.00K, a 89.39% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $423.00K 10-Q · filed 2026-08-11 | $299.00K derived: sum of 3 quarters · filed 2026-08-11 | $3.64M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$2.75M 10-Q · filed 2026-05-11 | -$2.87M derived: sum of 2 quarters · filed 2026-05-11 | $476.00K derived: sum of 3 quarters · filed 2026-05-11 | $3.86M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.22M derived: sum of 2 quarters · filed 2026-03-30 | $6.61M derived: sum of 3 quarters · filed 2026-08-11 | $4.13M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $3.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.73M derived: sum of 2 quarters · filed 2026-08-11 | $4.25M 10-Q · filed 2025-11-13 | $4.24M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $910.00K 10-Q · filed 2026-08-11 | $893.00K derived: sum of 3 quarters · filed 2026-08-11 | $4.04M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$2.48M 10-Q · filed 2026-05-11 | -$2.49M derived: sum of 2 quarters · filed 2026-05-11 | $650.00K derived: sum of 3 quarters · filed 2026-05-11 | $2.00M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.13M derived: sum of 2 quarters · filed 2026-03-30 | $4.47M derived: sum of 3 quarters · filed 2026-03-30 | $1.58M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $3.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.49M derived: sum of 2 quarters · filed 2025-11-13 | $1.59M 10-Q · filed 2025-11-13 | $3.11M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.55M 10-Q · filed 2025-08-13 | -$34.00K derived: sum of 3 quarters · filed 2025-08-13 | $1.00M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$2.90M 10-Q · filed 2025-05-15 | -$1.38M derived: sum of 2 quarters · filed 2025-05-15 | -$346.00K derived: sum of 3 quarters · filed 2025-05-15 | $921.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $2.55M derived: sum of 2 quarters · filed 2025-03-24 | $3.82M derived: sum of 3 quarters · filed 2025-03-24 | $3.31M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.30M derived: sum of 2 quarters · filed 2024-11-12 | $1.80M 10-Q · filed 2024-11-12 | $1.09M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $761.00K 10-Q · filed 2024-08-08 | $60.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.40M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$506.00K 10-Q · filed 2024-05-09 | -$1.21M derived: sum of 2 quarters · filed 2024-05-09 | $132.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.56M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$701.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $638.00K derived: sum of 2 quarters · filed 2024-03-27 | $2.07M derived: sum of 3 quarters · filed 2024-03-27 | $234.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.77M derived: sum of 2 quarters · filed 2023-11-09 | $935.00K 10-Q · filed 2023-11-09 | $1.78M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$404.00K 10-Q · filed 2023-08-09 | -$388.00K 10-Q · filed 2022-08-11 | $445.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.56M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.83M 10-Q · filed 2023-05-11 | -$985.00K derived: sum of 2 quarters · filed 2023-05-11 | $126.00K derived: sum of 3 quarters · filed 2023-05-11 | $659.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $849.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.96M derived: sum of 2 quarters · filed 2023-03-15 | $2.49M derived: sum of 3 quarters · filed 2023-03-15 | $2.21M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.64M derived: sum of 2 quarters · filed 2022-11-10 | $1.36M 10-Q · filed 2022-11-10 | $2.10M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $533.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $246.00K 10-Q · filed 2022-08-11 | $991.00K derived: sum of 3 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$287.00K 10-Q · filed 2022-05-12 | $458.00K derived: sum of 2 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $745.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$1.79M 10-K · filed 2022-03-23 | |||
| 2020-09-30 | -$2.54M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |